Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Free access | 10.1172/JCI129277

Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis

Yoko Kojima, Kelly Downing, Ramendra Kundu, Clint Miller, Frederick Dewey, Hope Lancero, Uwe Raaz, Ljubica Perisic, Ulf Hedin, Eric Schadt, Lars Maegdefessel, Tom Quertermous, and Nicholas J. Leeper

Find articles by Kojima, Y. in: JCI | PubMed | Google Scholar

Find articles by Downing, K. in: JCI | PubMed | Google Scholar

Find articles by Kundu, R. in: JCI | PubMed | Google Scholar

Find articles by Miller, C. in: JCI | PubMed | Google Scholar

Find articles by Dewey, F. in: JCI | PubMed | Google Scholar

Find articles by Lancero, H. in: JCI | PubMed | Google Scholar

Find articles by Raaz, U. in: JCI | PubMed | Google Scholar

Find articles by Perisic, L. in: JCI | PubMed | Google Scholar

Find articles by Hedin, U. in: JCI | PubMed | Google Scholar

Find articles by Schadt, E. in: JCI | PubMed | Google Scholar

Find articles by Maegdefessel, L. in: JCI | PubMed | Google Scholar

Find articles by Quertermous, T. in: JCI | PubMed | Google Scholar

Find articles by Leeper, N. in: JCI | PubMed | Google Scholar

Published May 1, 2019 - More info

Published in Volume 129, Issue 5 on May 1, 2019
J Clin Invest. 2019;129(5):2164–2164. https://doi.org/10.1172/JCI129277.
© 2019 American Society for Clinical Investigation
Published May 1, 2019 - Version history
View PDF

Related article:

Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis
Yoko Kojima, … , Tom Quertermous, Nicholas J. Leeper
Yoko Kojima, … , Tom Quertermous, Nicholas J. Leeper
Research Article

Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis

  • Text
  • PDF
Abstract

Genetic variation at the chromosome 9p21 risk locus promotes cardiovascular disease; however, it is unclear how or which proteins encoded at this locus contribute to disease. We have previously demonstrated that loss of one candidate gene at this locus, cyclin-dependent kinase inhibitor 2B (Cdkn2b), in mice promotes vascular SMC apoptosis and aneurysm progression. Here, we investigated the role of Cdnk2b in atherogenesis and found that in a mouse model of atherosclerosis, deletion of Cdnk2b promoted advanced development of atherosclerotic plaques composed of large necrotic cores. Furthermore, human carriers of the 9p21 risk allele had reduced expression of CDKN2B in atherosclerotic plaques, which was associated with impaired expression of calreticulin, a ligand required for activation of engulfment receptors on phagocytic cells. As a result of decreased calreticulin, CDKN2B-deficient apoptotic bodies were resistant to efferocytosis and not efficiently cleared by neighboring macrophages. These uncleared SMCs elicited a series of proatherogenic juxtacrine responses associated with increased foam cell formation and inflammatory cytokine elaboration. The addition of exogenous calreticulin reversed defects associated with loss of Cdkn2b and normalized engulfment of Cdkn2b-deficient cells. Together, these data suggest that loss of CDKN2B promotes atherosclerosis by increasing the size and complexity of the lipid-laden necrotic core through impaired efferocytosis.

Authors

Yoko Kojima, Kelly Downing, Ramendra Kundu, Clint Miller, Frederick Dewey, Hope Lancero, Uwe Raaz, Ljubica Perisic, Ulf Hedin, Eric Schadt, Lars Maegdefessel, Tom Quertermous, Nicholas J. Leeper

×

Original citation: J Clin Invest. 2014;124(3):1083–1097. https://doi.org/10.1172/JCI70391

Citation for this corrigendum: J Clin Invest. 2019;129(5):2164. https://doi.org/10.1172/JCI129277

During the assembly of Figure 6A and Supplemental Figure 4C, incorrect flow cytometry plots were included. The authors were able to provide the original data, and a corrected version of Figure 6A appears below. The online version of the supplemental data has been updated with the corrected version of Supplemental Figure 4C.

The authors regret the error.

Footnotes

See the related article at Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis.

Version history
  • Version 1 (May 1, 2019): Print issue publication

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need Help? E-mail the JCI

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts